XML 73 R62.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Assets $ 10,214.1   $ 10,214.1   $ 9,364.1
Interest expense (12.6) $ (12.3) (24.6) $ (24.5)  
Foreign Currency Transaction Gain (Loss), before Tax (1.1) 1.7 1.6 3.7  
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 414.0 (2,786.3) 497.4 (2,295.2)  
Marketable Securities, Unrealized Gain (Loss) 334.4 (2,895.4) 366.2 (2,473.2)  
Other Nonoperating Income (Expense) 16.2 18.2 53.4 52.6  
Other Nonoperating (Income) 0.6 1.7 1.2 2.3  
Net sales 651.6 638.5 1,237.0 1,249.3  
Cost of goods sold 306.3 283.4 585.7 568.2  
Gross profit 345.3 355.1 651.3 681.1  
Selling, general and administrative expense (207.7) (194.7) (416.5) (409.6)  
Research and Development Expense (60.5) (58.9) (134.0) (125.3)  
Life Science          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Net sales 262.8 250.5 491.4 492.2  
Cost of goods sold 114.5 105.9 214.7 215.9  
Depreciation, Depletion and Amortization 17.8 16.3 34.8 32.5  
Gross profit 148.3 144.6 276.7 276.3  
Other Operating Segment          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Net sales 0.0 0.0 0.0 0.5  
Cost of goods sold 0.0 0.0 0.0 0.6  
Depreciation, Depletion and Amortization 0.0 0.0 0.0 0.0  
Gross profit 0.0 0.0 0.0 (0.1)  
Clinical Diagnostics          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Net sales 388.8 388.0 745.6 756.6  
Cost of goods sold 191.8 177.5 371.0 351.7  
Depreciation, Depletion and Amortization 22.8 20.1 43.9 41.0  
Gross profit 197.0 210.5 374.6 404.9  
Operating Segments          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Gross profit 345.3 355.1      
Selling, general and administrative expense (207.7) (194.7) (416.5) (409.6)  
Research and Development Expense (60.5) (58.9) (134.0) (125.3)  
Operating Segments | Life Science          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Assets 309.8 308.8 309.8 308.8  
Operating Segments | Other Operating Segment          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Assets 0.0 0.0 0.0 0.0  
Operating Segments | Clinical Diagnostics          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Assets 489.0 495.0 489.0 495.0  
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Foreign Currency Transaction Gain (Loss), before Tax (1.1) 1.7 1.6 3.7  
Marketable Securities, Unrealized Gain (Loss) 334.4 (2,895.4) 366.2 (2,473.2)  
Other Nonoperating Income (Expense) 16.2 18.2 53.4 52.6  
Interest Expense | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment          
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]          
Interest expense $ (12.6) $ (12.3) $ 24.6 $ 24.5